These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 33466686)

  • 21. Displaying alphavirus physicochemical consensus antigens on immunogenic liposomes enhances antibody elicitation in mice.
    Huang WC; Baker WS; Lovell JF; Schein CH
    Virology; 2024 Jun; 597():110152. PubMed ID: 38968676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum.
    Arakawa T; Komesu A; Otsuki H; Sattabongkot J; Udomsangpetch R; Matsumoto Y; Tsuji N; Wu Y; Torii M; Tsuboi T
    Infect Immun; 2005 Nov; 73(11):7375-80. PubMed ID: 16239536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional evaluation of malaria Pfs25 DNA vaccine by in vivo electroporation in olive baboons.
    Kumar R; Nyakundi R; Kariuki T; Ozwara H; Nyamongo O; Mlambo G; Ellefsen B; Hannaman D; Kumar N
    Vaccine; 2013 Jun; 31(31):3140-7. PubMed ID: 23684840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel plant-produced Pfs25 fusion subunit vaccine induces long-lasting transmission blocking antibody responses.
    Jones RM; Chichester JA; Manceva S; Gibbs SK; Musiychuk K; Shamloul M; Norikane J; Streatfield SJ; van de Vegte-Bolmer M; Roeffen W; Sauerwein RW; Yusibov V
    Hum Vaccin Immunother; 2015; 11(1):124-32. PubMed ID: 25483525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A plant-produced Pfs25 VLP malaria vaccine candidate induces persistent transmission blocking antibodies against Plasmodium falciparum in immunized mice.
    Jones RM; Chichester JA; Mett V; Jaje J; Tottey S; Manceva S; Casta LJ; Gibbs SK; Musiychuk K; Shamloul M; Norikane J; Mett V; Streatfield SJ; van de Vegte-Bolmer M; Roeffen W; Sauerwein RW; Yusibov V
    PLoS One; 2013; 8(11):e79538. PubMed ID: 24260245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice.
    Healy SA; Anderson C; Swihart BJ; Mwakingwe A; Gabriel EE; Decederfelt H; Hobbs CV; Rausch KM; Zhu D; Muratova O; Herrera R; Scaria PV; MacDonald NJ; Lambert LE; Zaidi I; Coelho CH; Renn JP; Wu Y; Narum DL; Duffy PE
    J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33561016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever.
    An SJ; Scaria PV; Chen B; Barnafo E; Muratova O; Anderson C; Lambert L; Chae MH; Yang JS; Duffy PE
    Vaccine; 2018 May; 36(21):2978-2984. PubMed ID: 29681410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TLR-adjuvanted nanoparticle vaccines differentially influence the quality and longevity of responses to malaria antigen Pfs25.
    Thompson EA; Ols S; Miura K; Rausch K; Narum DL; Spångberg M; Juraska M; Wille-Reece U; Weiner A; Howard RF; Long CA; Duffy PE; Johnston L; O'Neil CP; Loré K
    JCI Insight; 2018 May; 3(10):. PubMed ID: 29769448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metallated porphyrin based porous organic polymers as efficient electrocatalysts.
    Lu G; Zhu Y; Xu K; Jin Y; Ren ZJ; Liu Z; Zhang W
    Nanoscale; 2015 Nov; 7(43):18271-7. PubMed ID: 26486413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of Pfs25 expressed from multiple soluble expression platforms for use as transmission-blocking vaccine candidates.
    Lee SM; Wu CK; Plieskatt J; McAdams DH; Miura K; Ockenhouse C; King CR
    Malar J; 2016 Aug; 15(1):405. PubMed ID: 27515826
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate.
    Radtke AJ; Anderson CF; Riteau N; Rausch K; Scaria P; Kelnhofer ER; Howard RF; Sher A; Germain RN; Duffy P
    Sci Rep; 2017 Jan; 7():40312. PubMed ID: 28091576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cobalt(III)-Mediated Permanent and Stable Immobilization of Histidine-Tagged Proteins on NTA-Functionalized Surfaces.
    Wegner SV; Schenk FC; Spatz JP
    Chemistry; 2016 Feb; 22(9):3156-62. PubMed ID: 26809102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Malaria Derived Glycosylphosphatidylinositol Anchor Enhances Anti-Pfs25 Functional Antibodies That Block Malaria Transmission.
    Kapoor N; Vanjak I; Rozzelle J; Berges A; Chan W; Yin G; Tran C; Sato AK; Steiner AR; Pham TP; Birkett AJ; Long CA; Fairman J; Miura K
    Biochemistry; 2018 Feb; 57(5):516-519. PubMed ID: 29323879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New adenovirus-based vaccine vectors targeting Pfs25 elicit antibodies that inhibit Plasmodium falciparum transmission.
    McGuire KA; Miura K; Wiethoff CM; Williamson KC
    Malar J; 2017 Jun; 16(1):254. PubMed ID: 28619071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthetic peptides from P. falciparum sexual stage 25-kDa protein induce antibodies that react with the native protein: the role of IL-2 and conformational structure on immunogenicity of Pfs25.
    Quakyi IA; Miller LH; Good MF; Ahlers JD; Isaacs SN; Nunberg JH; Houghten RA; Keister DB; Coligan JE; Moss B
    Pept Res; 1995; 8(6):335-44. PubMed ID: 8838417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A viral vectored prime-boost immunization regime targeting the malaria Pfs25 antigen induces transmission-blocking activity.
    Goodman AL; Blagborough AM; Biswas S; Wu Y; Hill AV; Sinden RE; Draper SJ
    PLoS One; 2011; 6(12):e29428. PubMed ID: 22216279
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure and mechanism of a transmission blocking vaccine candidate protein Pfs25 from P. falciparum: a molecular modeling and docking study.
    Sharma B
    In Silico Biol; 2008; 8(3-4):193-206. PubMed ID: 19032156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative functional potency of DNA vaccines encoding Plasmodium falciparum transmission blocking target antigens Pfs48/45 and Pfs25 administered alone or in combination by in vivo electroporation in rhesus macaques.
    Datta D; Bansal GP; Grasperge B; Martin DS; Philipp M; Gerloff D; Ellefsen B; Hannaman D; Kumar N
    Vaccine; 2017 Dec; 35(50):7049-7056. PubMed ID: 29132995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles.
    Kumar R; Ray PC; Datta D; Bansal GP; Angov E; Kumar N
    Vaccine; 2015 Sep; 33(39):5064-71. PubMed ID: 26299750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.
    Wu Y; Ellis RD; Shaffer D; Fontes E; Malkin EM; Mahanty S; Fay MP; Narum D; Rausch K; Miles AP; Aebig J; Orcutt A; Muratova O; Song G; Lambert L; Zhu D; Miura K; Long C; Saul A; Miller LH; Durbin AP
    PLoS One; 2008 Jul; 3(7):e2636. PubMed ID: 18612426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.